Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma.

ABSTRACT:

Purpose

Outcomes for patients with glioblastoma (GBM) remain poor despite multimodality treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options due to the lack of tumor immunogenicity. Several clinical trials have reported promising results with cancer vaccines. To date, studies have used data from a single tumor site to identify targetable antigens, but this approach limits the antigen pool and is antithetical to the heterogeneity of GBM. We have implemented multisector sequencing to increase the pool of neoantigens across the GBM genomic landscape that can be incorporated into personalized peptide vaccines called NeoVax.

Patients and methods

In this study, we report the findings of four patients enrolled onto the NeoVax clinical trial (NCT0

SUBMITTER: Johanns TM 

PROVIDER: S-EPMC11215407 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature